These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8791945)

  • 41. Consensus guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care setting.
    Whitaker MJ
    Pharmacoeconomics; 1998; 14 Suppl 2():5-10. PubMed ID: 10344923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting.
    Klok RM; Arents NL; de Vries R; Thijs JC; Brouwers JR; Kleibeuker JH; Postma MJ
    Clin Ther; 2005 Oct; 27(10):1647-57. PubMed ID: 16330302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial management strategies for dyspepsia.
    Delaney BC; Moayyedi P; Forman D
    Cochrane Database Syst Rev; 2003; (2):CD001961. PubMed ID: 12804417
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of routine endoscopic biopsies for Helicobacter pylori detection in patients with non-ulcer dyspepsia.
    Makris N; Crott R; Fallone CA; Bardou M; Barkun A
    Gastrointest Endosc; 2003 Jul; 58(1):14-22. PubMed ID: 12838214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The burden of gastrointestinal disease: implications for the provision of care in the UK.
    Hellier MD; Williams JG
    Gut; 2007 Feb; 56(2):165-6. PubMed ID: 17303603
    [No Abstract]   [Full Text] [Related]  

  • 46. Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care.
    Verma S; Giaffer MH
    Dig Dis Sci; 2002 Jul; 47(7):1567-74. PubMed ID: 12141818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controversy and consensus in the management of upper gastrointestinal disease in primary care. The International Gastro Primary Care Group.
    Whitaker MJ; Brun J; Carelli F
    Int J Clin Pract; 1997 Jun; 51(4):239-43. PubMed ID: 9287266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary care for women. Management and treatment of gastrointestinal disorders.
    Shaw B
    J Nurse Midwifery; 1996; 41(2):155-72. PubMed ID: 8691276
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Annual Costs of Care for Pediatric Irritable Bowel Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome.
    Hoekman DR; Rutten JM; Vlieger AM; Benninga MA; Dijkgraaf MG
    J Pediatr; 2015 Nov; 167(5):1103-8.e2. PubMed ID: 26329806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dyspepsia and Helicobacter pylori: test, treat or investigate?
    Harris A
    Eur J Gastroenterol Hepatol; 1999 Jun; 11 Suppl 1():S31-5. PubMed ID: 10443910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Hanlon I; Hewitt C; Bell K; Phillips A; Mikocka-Walus A
    Aliment Pharmacol Ther; 2018 Aug; 48(3):244-259. PubMed ID: 29901820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease.
    Haycox A; Dubois D; Butterworth M
    Pharmacoeconomics; 1998; 14 Suppl 2():39-56. PubMed ID: 10344922
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reducing community dyspepsia drug costs: a controlled trial.
    Valori RM; Brown CM; Strangeways P; Bradburn M
    Gut; 2001 Oct; 49(4):495-501. PubMed ID: 11559645
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An osteopathic approach to gastrointestinal disease: somatic clues for diagnosis and clinical challenges associated with Helicobacter pylori antibiotic resistance.
    Smilowicz A
    J Am Osteopath Assoc; 2013 May; 113(5):404-16. PubMed ID: 23667194
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Practice patterns for managing Helicobacter pylori infection and upper gastrointestinal symptoms.
    Howden CW; Blume SW; de Lissovoy G
    Am J Manag Care; 2007 Jan; 13(1):37-44. PubMed ID: 17227202
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and impact of upper and lower gastrointestinal symptoms in the Greek urban general population.
    Papatheodoridis GV; Karamanolis DG
    Scand J Gastroenterol; 2005 Apr; 40(4):412-21. PubMed ID: 16028435
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guidelines for the management of Helicobacter pylori-related upper gastrointestinal diseases. Irish Helicobacter Pylori Study Group.
    Buckley M; Culhane A; Drumm B; Keane C; Moran AP; O'Connor HJ; Collins J; Kelleher D; McAvinchey D; Sloan J; O'Morain C
    Ir J Med Sci; 1996; 165 Suppl 5():1-11. PubMed ID: 8990665
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Motility and functional gastrointestinal disorders].
    Mearin F; Rey E; Balboa A
    Gastroenterol Hepatol; 2014 Sep; 37 Suppl 3():3-13. PubMed ID: 25294261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Herbal Preparation STW 5 for Functional Gastrointestinal Disorders: Clinical Experience in Everyday Practice.
    Lapina TL; Trukhmanov AS
    Dig Dis; 2017; 35 Suppl 1():30-35. PubMed ID: 29421814
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.